AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ULTRAGENYX PHARMACEUTICAL · Biopharma company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 15, 2025

Income

$38,000.00

What the client paid this registrant for the period.

Client based in

California

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

- ultrarare disease - newborn screening - pediatric priority review voucher

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.